Abstract
No public abstract is available from the verified source records.
Lingya Yao
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment
10.1093/ecco-jcc/jjz180 · 2020
Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s disease
10.1053/j.gastro.2018.06.035 · 2018
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial
10.1016/s0140-6736(22)00688-2 · 2022
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn’s disease: A Canadian multi-center study
2023
Clinical, endoscopic, and radiological effectiveness of ustekinumab in bio-naive versus bio-experienced patients with Crohn’s disease: Real-world experience from a large Canadian center
10.1093/ibd/izac149 · 2023
No additional external references are available.